FL118
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


FL118
Description:
FL118 (10,11- (Methylenedioxy) -20 (S) -camptothecin), a Camptothecin (HY-16560) analogue, is a potent and orally active survivin inhibitor. FL118 binds to oncoprotein DDX5 (p68) to dephosphorylates and degrades DDX5. FL118 can be used for the research of cancer[1][2].Product Name Alternative:
10,11- (Methylenedioxy) -20 (S) -camptothecinUNSPSC:
12352005Hazard Statement:
H301+H311+H331Target:
Apoptosis; IAP; SurvivinType:
Reference compoundRelated Pathways:
ApoptosisApplications:
Cancer-programmed cell deathField of Research:
CancerAssay Protocol:
https://www.medchemexpress.com/fl118.htmlPurity:
99.40Solubility:
DMSO : 1 mg/mL (ultrasonic; warming; heat to 60°C)Smiles:
O=C1[C@](O)(CC)C(C=C2C3=NC4=CC5=C(C=C4C=C3CN2C6=O)OCO5)=C6CO1Molecular Formula:
C21H16N2O6Molecular Weight:
392.36Precautions:
H301+H311+H331References & Citations:
[1]Zhao H, et al. FL118, a novel anticancer compound, inhibits proliferation and migration of ovarian cancer cells via up-regulation of cytoglobin in vivo and in vitro[J]. Translational Cancer Research, 2017, 6 (6) :1294-1304.|[2]Ling X, et al. FL118, acting as a 'molecular glue degrader', binds to dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy. Clin Transl Med. 2022 May;12 (5) :e881.|[3]Wu G, et al. Synthesis of novel 10,11-methylenedioxy-camptothecin glycoside derivatives and investigation of their anti-tumor effects in vivo. RSC Adv. 2019 Apr 9;9 (20) :11142-11150. |[4]Ling X, et, al. FL118, a novel camptothecin analogue, overcomes irinotecan and topotecan resistance in human tumor xenograft models. Am J Transl Res. 2015 Oct 15;7 (10) :1765-81.Shipping Conditions:
Room TemperatureStorage Conditions:
-20°C, 3 years; 4°C, 2 years (Powder)Scientific Category:
Reference compound1Clinical Information:
Phase 1CAS Number:
[135415-73-5]
